|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||4.2450 - 4.2450|
|52 Week Range||3.8000 - 7.6099|
|Beta (5Y Monthly)||1.32|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Medigene AG (FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, has received approval from the Dutch regulatory authority (the Central Committee on Research Involving Human Subjects, CCMO) to begin a first clinical trial of MDG1021. MDG1021, which targets the antigen HA-1, thus becomes Medigene’s second proprietary T cell receptor-modified T cell (TCR-T) immunotherapy candidate to enter clinical development.
MARTINSRIED, Germany and MUNICH, Germany, June 22, 2020 -- Medigene AG (Medigene, FSE: MDG1), a clinical stage immuno-oncology company focusing on the development of T cell.
By John Vandermosten, CFA NASDAQ:PHIO READ THE FULL PHIO RESEARCH REPORT Milestones: ‣ Partnership/Sale of Dermatology and Ophthalmology Programs – TBD ‣ Expansion of collaboration with Helmholtz Zentrum München & Medigene – March 2020 ‣ IND enabling study results for PH-762 – 2020 ‣ PH-762 (ACT – Melanoma with partner) into clinic – 2H:20 ‣ PH-762 (IT – Melanoma) – 2021 ‣ PH-804 (ACT – with